Multidrug resistant Tuberculosis
| dc.contributor.author | Elhashmy, Hadeel | |
| dc.date.accessioned | 2019-06-25T09:04:01Z | |
| dc.date.available | 2019-06-25T09:04:01Z | |
| dc.date.issued | 2019-04-01 | |
| dc.description | Tuberculosis remains a major cause of morbidity and mortality globally, one of the causes are multidrug resistant tuberculosis (MDR-TB). MDR-TB refers to tuberculosis that is resistant to both rifampicin and isoniazid. Almost 20% of all TB strains worldwide are resistant to at least one major TB drug, approximately 10% are isoniazid monoresistant . Multidrug resistant tuberculosis with additional resistance to any fluoroquinolone (such as ofloxacin or moxifloxacin) and also any one of the three second line injectable agents (amikacin, capreomycin,kanamycin)is designated as extensively drug resistant tuberculosis (1). Rapid diagnosis and effective treatment are two of the most important strategies tuberculosis(TB)control program to prevent ongoing transmission of disease and to improve patient outcomes | en_US |
| dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/932 | |
| dc.language.iso | en | en_US |
| dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.title | Multidrug resistant Tuberculosis | en_US |
| dc.type | Other | en_US |